natgillin/translations-raw huggingface dataset:
The beta2-adrenoceptor agonist according to claim 1, wherein said beta2-adrenoceptor agonist is provided as the enantiomerically pure or as the enantiomerically enriched R-enantiomer of the beta2-adrenoceptor agonist selected from the group consisting of Amiterol; Bamethan; Bitolterol; Butaxamine; Carbuterol; Cimaterol; Colterol; Clenbuterol; Clorprenaline; Colterol; Deterenol; Dioxethedrin; Etafedrine; Ethylnorepinephrine; Fenoterol; Indacaterol; Isoproterenol; Mabuterol; Meluadrine; Nardeterol; Norbudrine; Norepinephrine; Orciprenaline; Picumeterol; Pirbuterol; Quinprenaline; Reproterol; Salbutamol; Salmeterol; Soterenol; Sulfonterol; Terbutaline; Tulobuterol; Zinterol; and a pharmaceutically acceptable salt thereof. 
Agonist beta2-adrenoceptora prema zahtjevu 1, naznačen time da je navedeni beta2- agonist adrenoceptora predviđen kao enantiomerno čist ili kao enantiomerno obogaćen R-enantiomer agonista beta2-adrenoceptora odabran iz skupine koja se sastoji od Amiterola; Bametana; Bitolterola; Butaksamina; Karbuterola; Cimaterola; Kolterola; Klenbuterola; Klorprenalina; Kolterola; Deterenola; Dioksetedrina; Etafedrina; Etilnorepinefrina; Fenoterola; Indakaterola; Izoproterenola; Mabuterola; Meluadrina; Nardeterola; Norbudrina; Norepinefrina; Orciprenalina; Pikumeterola; Pirbuterola; Kvinprenalina; Reproterola; Salbutamola; Salmeterola; Soterenola; Sulfonterola; Terbutalina; Tulobuterola; Zinterola; i njegova farmaceutski prihvatljiva sol.
The beta2-adrenoceptor agonist according to claim 1, wherein said beta2-adrenoceptor agonist is provided as the diastereomeric pure or as the diastereomeric enriched RS or RR isomer of the beta2-adrenoceptor agonist selected from the group consisting of Flerobuterol, Formoterol, Hexoprenaline, Isoetarine, Procaterol, Protokylol, Rimiterol, Salmefamol and Zilpaterol, and a pharmaceutically acceptable salt thereof. 
Agonist beta2-adrenoceptora prema zahtjevu 1, naznačen time da je navedeni agonist beta2-adrenoceptora predviđen kao diastereomerno čist ili kao diastereomerno obogaćen RS ili RR izomer agonista beta2-adrenoceptora odabran iz skupine koja se sastoji od Flerobuterola, Formoterola, Heksoprenalina, Izoetarina, Prokaterola, Protokilola, Rimiterola, Salmefamola i Zilpaterola, i njegova farmaceutski prihvatljiva sol.
The composition according to claim 18, wherein the beta2-adrenoceptor agonist is selected from enantiomerically pure or enantiomerically enriched R-enantiomer of Amiterol, Bamethan, Bitolterol, Butaxamine, Carbuterol, Cimaterol, Colterol, Clenbuterol, Clorprenaline, Colterol, Deterenol, Dioxethedrin, Etafedrine, Ethylnorepinephrine, Fenoterol, Indacaterol, Isoproterenol, Mabuterol, Meluadrine, Nardeterol, Norbudrine, Norepinephrine, Orciprenaline, Picumeterol, Pirbuterol, Quinprenaline, Reproterol, Salbutamol, Salmeterol, Soterenol, Sulfonterol, Terbutaline, Tulobuterol, Zinterol, and a pharmaceutically acceptable salt thereof. 
Pripravak prema zahtjevu 18, naznačen time da je agonist beta2-adrenoceptora odabran od enantiomerno čistog ili enantiomerno obogaćenog R-enantiomera od Amiterola, Bametana, Bitolterola, Butaksamina, Karbuterola, Cimaterola, Kolterola, Klenbuterola, Klorprenalina, Kolterola, Deterenola, Dioksetedrina, Etafedrina, Etilnorepinefrina, Fenoterola, Indakaterola, Izoproterenola, Mabuterola, Meluadrina, Nardeterola, Norbudrina, Norepinefrina, Orciprenalina, Pikumeterola, Pirbuterola, Kvinprenalina, Reproterola, Salbutamola, Salmeterola, Soterenola, Sulfonterola, Terbutalinea, Tulobuterola, Zinterola, i njegova farmaceutski prihvatljiva sol.
The composition according to claim 18, wherein the composition is in the form of an emulsion, a cream, a lotion, a gel, a liniment, an ointment, a pasta or a foam. 
Pripravak prema zahtjevu 18, naznačen time da je pripravak u obliku emulzije, kreme, losiona, gela, melema, masti, paste ili pjene.
A polynucleotide comprising a nucleotide sequence encoding a polypeptide having a single N-terminal kringle domain which is at least 90% identical to the kringle 1 domain of native human plasminogen; and a C-terminal domain which is at least 90% identical to the activation site and serine protease domain of human plasminogen, wherein the polypeptide binds to immobilized lysine and can be activated by a plasminogen activator. 
Polinukleotid koji sadrži nukleotidnu sekvence koja služi za enkodiranje polipeptida te sadrži jednu N-terminalnu kringl domenu koja je najmanje 90% istovjetna kringl 1 domeni nativnog ljudskog plazminogena; i C-terminalnu domenu koja je najmanje 90% istovjetna mjestu aktivacije i domeni serin proteaze ljudskog plazminogena, naznačen time da polipeptid veže u imobiliziranom lizinu i može biti aktiviran pomoću aktivatora plazminogena.
The polynucleotide of claim 1 or 2, wherein the encoded polypeptide is at least 90% identical to the sequence shown in SEQ ID NO: 2. 
Polinukleotid prema zahtjevu 1 ili 2, naznačen time da je enkodirani polipeptid najmanje 90% istovjetan sekvenci prikazanoj u SEQ ID NO: 2.
A polypeptide encoded by the nucleic acid according to any one of claims 1 to 7. 
Polinukleotid enkodiran uz pomoć nukleinske kiseline, naznačen time da je prema bilo kojem od zahtjeva 1 do 7.
The polypeptide of claim 8, wherein the polypeptide exhibits a fibrinolytic activity that is inhibited by a2-antiplasmin at a rate of inhibition that is at least about 5- fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by a2-antiplasmin. 
Polipeptid prema zahtjevu 8, naznačen time da polipeptid pokazuje fibrinolitičku aktivnost koja je inhibirana s a2-antiplazminom pri stupnju inhibicije koji je najmanje oko 5 puta brži nego što je stupanj inhibicije fibrinolitičke aktivnosti mini-plazmina sa a2-antiplazminom.
The polypeptide of any one of claims 8 to 13, wherein the polypeptide exhibits higher binding affinity for partially cleaved fibrin than the binding affinity for partially cleaved fibrin of mini-plasmin. 
Polipeptid prema bilo kojem od zahtjeva 8 do 13, naznačen time da polipeptid pokazuje viši afinitet vezanja za djelomično rascijepan fibrin nego afinitet vezanja za djelomično rascijepan fibrin mini-plazmina.
A pharmaceutical composition according to claim 18 for the treatment of a gynaecological disorder. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 18, naznačen time što je namijenjen liječenju ginekološkog poremećaja.
A topical pharmaceutical formulation comprising a compound of formula (I): or salt or solvate thereof for use in the treatment of ocular neovascular disorders by direct administration to the eye. 
Topikalna farmaceutska formulacija koja sadrži spoj formule (I): [image] ili njegovu sol ili solvat, naznačena time što je namijenjena upotrebi u liječenju neovaskularnih poremećaja oka izravnom primjenom u oko.
A topical formulation for use according to claims 1-3 in the form of eye drops, wherein the compound of formula 1, 1'; or 1" is dissolved or suspended in a suitable carrier. 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevima 1-3, u obliku kapi za oči, naznačena time što spoj formule I, I' ili I'' je otopljen ili suspendiran u pogodnoj podlozi.
A topical formulation for use according to claims 1-4 for administering in conjunction with one or more additional therapeutic agents for the treatment of neovascular disorders. 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevima 1-4, naznačena time što je namijenjena za primjenu uz jedno ili više dodatnih terapijskih sredstava za liječenje neovaskularnih poremećaja.
A topical formulation for use according to claims 5-6 wherein the one or more additional therapeutic agents are administered separately. 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevima 5-6, naznačena time što jedno ili više dodatnih terapijskih sredstava se primijenjuje odvojeno.
A topical formulation for use according o claims 1-8 wherein the ocular neovascular disorder is a choroidal neovascular disorder or a retinal neovascular disorders. 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevima 1-8, naznačena time što neovaskularni poremećaj oka je neovaskularni poremećaj žilnice ili neovaskularni poremećaji mrežnice.
A topical formulation for use according to claim 9 wherein the ocular neovascular disorder is exudative age-related macular degeneration (AMD), angiod streaks, pathological myopia, ocular histoplasmosis syndrome, breaks in Bruch's membrane, macular edema (including diabetic macular edema), sarcoidosis, uveitis, atrophic AMD, keratoconus, Sjogren's syndrome, myopia, ocular tumors, corneal graft rejection, corneal injury, neovascular glaucoma, corneal ulceration, corneal scarring, proliferative vitreoretinopathy, retinopathy of prematurity, retinal degeneration, chronic glaucoma, retinal detachment, or sickle cell retinpathy. 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevom 9, naznačena time što neovaskularni poremećaj oka je eksudativna staračka degeneracija makule (AMD), angiodne strije, patološka miopija, sindrom histoplasmoze oka, rupture Bruchove membrane, makularni edem (uključujući dijabetični makularni edem), sarkoidoza, uveitis, atrofični AMD, keratokonus, Sjögrenov sindrom, miopija, tumori oka, odbacivanje presađene rožnice, ozljeda rožnice, neovaskularni glaukom, ulceracija rožnice, ožiljavanje rožnice, proliferativna vitreoretinopatija, prematurna retinopatija, degeneracija mrežnice, kronični glaukom, odljuštenje rožnice ili drepanocitozna retinpatija.
A topical formulation for use according to claim 10 wherein the ocular neovascular disorder is exudative age-related macular degeneration (AMD). 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevom 10, naznačena time što neovaskularni poremećaj oka je eksudativna staračka degeneracija makule (AMD).
Use of a compound of formula (I):- or a salt or solvate thereof in the manufacture of a medicament for treatment of ocular neovascular disorders by topical application direct to the eye. 
Upotreba spoja formule (I): [image] ili njegove soli ili solvata, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje neovaskularnih poremećaja oka topikalnom primjenom izravno u oko.
Use according to claims 15-17 wherein the medicament is In the form of eye drops, wherein the compound of formula 1 1' or 1" is dissolved or suspended in suitable solvent. 
Upotreba u skladu s patentnim zahtjevima 15-17, naznačena time što medikament je u obliku kapi za oči, gdje spoj formule I' ili I'' je otopljen ili suspendiran u pogodnom otapalu.
Use according to claims 15-18 wherein the medicament is administered in conjunction with one or more additional therapeutic agents for the treatment of neovascular disorders. 
Upotreba u skladu s patentnim zahtjevima 15-18, naznačena time što medikament se primijenjuje uz jedno ili više dodatnih terapijskih sredstava za liječenje neovaskularnih poremećaja.
Use according to claims 15-22 wherein the ocular neovascular disorder is a choroidal neovascular disorder or a retinal neovascular disorder. 
Upotreba u skladu s patentnim zahtjevima 15-22, naznačena time što neovaskularni poremećaj oka je neovaskularni poremećaj žilnice ili neovaskularni poremećaj mrežnice.
Use according to claim 23 wherein the ocular neovascular disorder is exudative age-related macular degeneration (AMD), angiod streaks, pathological myopia, ocular histoplasmosis syndrome, breaks in Bruch's membrane, macular edema (including diabetic macular edema), sarcoidosis, uveitis, atrophic AMD, keratoconus, Sjogren's syndrome, myopia, ocular tumors, corneal graft rejection, corneal injury, neovascular glaucoma, corneal ulceration, corneal scarring, proliferative vitreoretinopathy, retinopathy of prematurity, retinal degeneration, chronic glaucoma, retinal detachment, or sickle cell retinpathy. 
Upotreba u skladu s patentnim zahtjevom 23, naznačena time što neovaskularni poremećaj oka je eksudativna staračka degeneracija makule (AMD), angiodne strije, patološka miopija, sindrom histoplasmoze oka, rupture Bruchove membrane, makularni edem (uključujući dijabetični makularni edem), sarkoidoza, uveitis, atrofični AMD, keratokonus, Sjögrenov sindrom, miopija, tumori oka, odbacivanje presađene rožnice, ozljeda rožnice, neovaskularni glaukom, ulceracija rožnice, ožiljavanje rožnice, proliferativna vitreoretinopatija, prematurna retinopatija, degeneracija mrežnice, kronični glaukom, odljuštenje rožnice ili drepanocitozna retinpatija.
A compound of formula (I) or a salt or solvate thereof: for use in the treatment of ocular neovascular disorders by topical administration directly to the eye. 
Spoj formule (I) ili njegova sol ili solvat: naznačen time što je namijenjen liječenju neovaskularnih poremećaja oka topikalnom primjenom izravno u oko.
An oral formulation for use according to claims 1-3 for administering in conjunction with one or more additional therapeutic agents for the treatment of neovascular disorders. 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevima 1-4, naznačena time što je namijenjena za primjenu uz jedno ili više dodatnih terapijskih sredstava za liječenje neovaskularnih poremećaja.
An oral formulation for use according to claims 4-5 wherein the one or more additional therapeutic agents are administered separately. 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevima 5-6, naznačena time što jedno ili više dodatnih terapijskih sredstava se primijenjuje odvojeno.
An oral formulation for use according to claims 1-7 wherein the ocular neovascular disorder is a choroidal neovascular disorder or a retinal neovascular disorder. 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevima 1-8, naznačena time što neovaskularni poremećaj oka je neovaskularni poremećaj žilnice ili neovaskularni poremećaji mrežnice.
An oral formulation for use according to claim 8 wherein the ocular neovascular disorder is exudative age-related macular degeneration (AMD), angiod streaks, pathological myopia, ocular histoplasmosis syndrome, breaks in Bruch's membrane, macular edema (including diabetic macular edema), sarcoidosis, uveitis, atrophic AMD, keratoconus, Sjogren's syndrome, myopia, ocular tumours, corneal graft rejection, corneal injury, neovascular glaucoma, corneal ulceration, corneal scarring, proliferative vitreoretinopathy, retinopathy of prematurity, retinal degeneration, chronic glaucoma, retinal detachment, or sickle cell retinpathy. 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevom 9, naznačena time što neovaskularni poremećaj oka je eksudativna staračka degeneracija makule (AMD), angiodne strije, patološka miopija, sindrom histoplasmoze oka, rupture Bruchove membrane, makularni edem (uključujući dijabetični makularni edem), sarkoidoza, uveitis, atrofični AMD, keratokonus, Sjögrenov sindrom, miopija, tumori oka, odbacivanje presađene rožnice, ozljeda rožnice, neovaskularni glaukom, ulceracija rožnice, ožiljavanje rožnice, proliferativna vitreoretinopatija, prematurna retinopatija, degeneracija mrežnice, kronični glaukom, odljuštenje rožnice ili drepanocitozna retinpatija.
Semisolid mucoadhesive formulation, characterized in that it comprises: 
Polučvrsta mukoadhezivna formulacija, naznačena time što sadrži:
Formulation in accordance with claim 1, wherein the fat / lipophilic component is selected from the group formed by paraffin, vaseline, mineral oil, vegetable oils and hydrogenated vegetable oils. 
Formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što masnu odnosno lipofilnu komponentu se bira iz skupine koju čine parafin, vazelin, mineralno ulje, biljna ulja i hidrogenirana biljna ulja.
Process for the preparation of the formulations in accordance with preceding claims, characterized in that it comprises the steps of: 
Postupak priprave formulacija u skladu s prethodnim patentnim zahtjevima, naznačen time što se sastoji u koracima:
3- adding the neutralizing agent to the mixture of the previous step, stirring it until attaining the suitable pH for polymer gelling and for vaginal application (approximately between 4 and 5), 
dodavanja sredstva za neutraliziranje u smjesu iz prethodnog koraka, uz miješanje, dok se ne postigne pH između 4 i 5, pogodan za želiranje polimera i primjenu u vaginu,
4' adding the mixture of step 2' to the dispersion of step 1', 
' dodavanja smjese iz koraka 2' u disperziju iz koraka 1',
The method of any of claims 1 to 11, wherein the 1st reactant is a compound of formula R4(CO)R5 VI, wherein R4 is selected from the group consisting of hydrogen, C1-6-alkyl, alkenyl, alkynyl, C3-10-cycloalkyl, aryl, heteroaryl, aralkyl and dialkylamino, and wherein R5 is C1-6-alkyl, alkenyl, alkynyl, C3-10-cycloalkyl, aryl, heteroaryl, aralkyl, dialkylamino, di-C3-10-cycloalkylamino, diarylamino and diheteroarylamino. 
Postupak prema bilo kojem zahtjevu od 1 do 11, naznačen time, da je prvi reaktant spoj formule (CO)R5 VI, gdje R4 je odabaran iz skupine koja se sastoji od vodika, C1-6-alkila, alkenila, alkinila, C3-10-cikloalkila, arila, heteroarila, aralkila i dialkilamina, dok je R5 odabran iz skupine koja se sastoji od C1-6-alkila, alkenila, alkinila, C3-10-cikloalkila, arila, heteroarila, aralkila, dialkilamina, di-C3-10-cikloalkilamina, diarilamina i diheteroarilamina.
reacting the compound of the Formula V with tosylchloride in situ to form a sulphonate ester in the presence of a suitable base and toluene to form the compound of the Formula II. 
reakcije spoja prema formuli V sa pogodnim sredstvom za sulfoniranje in situ koji tvore sulfonatni ester u prisutnosti pogodne baze i toluena koji tvore spoj prema formuli IIa.
Method according to one of claims 7 and 8, characterized in that the tucking roll (4) and the swivel axis of the pivot point (12a,12b) of the at least one pivoted lever (11) are adjusted in such a way that they are situated above the level of the coiling-spool's longitudinal axis (19). 
Postupak prema jednom od zahtjeva 7 i 8, naznačen time, da se namještaju valjak za nabiranje (4) i pokretna osovina stožerne točke (12a, 12b) barem jedne stožerne poluge (11) na takav način, da oni budu postavljeni iznad razine uzdužne osi (19) namotnog kalema.
Method according to claim 11, characterized in that the pivot point (12a,12b) of the pivoted lever (11) is fixed by forcing the secondary pivoting (15) arm against a fixed stop (18a, 18b). 
Postupak prema zahtjevu 11, naznačen time, da se učvršćuje stožerna točka (12a, 12b) stožerne poluge (11) pomoću prisiljavanja pomoćne stožerne ručice (15) prema učvršćenom zaporu (18a, 18b).
in the application of vapour of a solution of hydrogen peroxide and residual gas plasma from atmospheric air, excited by pulsed electrical discharge; 
se primjenjuje isparena otopina vodikovog peroksida i rezidualna plinska plazma iz atmosferskog zraka, pobuđena pulsnim električnim pražnjenjem;
in that the vacuum system further comprises at least one liquid ring pump (5), connected in parallel and linked to said chamber (1) by valves (6) and (7); 
vakuumski sustav dodatno uključuje najmanje jednu crpku s tekućim prstenom (5) koja je spojena paralelno i povezana s navedenom komorom (1) pomoću ventila (6) i (7);
in that the interior of the chamber (1) is provided with a stand (12), composed of flat surfaces, which, as well as serving to give support to the articles (M) which are to be sterilized, also comprise electrodes (E) at which the plasma is formed for the sterilization process; 
se u unutrašnjosti komore (1) nalazi stalak (12), koji čine ravne površine, koje, osim što služe kao nosači za predmete (M) koje treba sterilizirati, također uključuju elektrode (E) na kojima nastaje plazma koja se koristi u postupku sterilizacije;
in that the programmable logic controller (14) is responsible for: 
je namjena programabilnog logičkog kontrolera (14):
Reduction of the pressure on the articles which are to be sterilized by means of the liquid ring pump (5) following the mechanical vacuum pump (4) in order to attain the required pressure of the plasma; 
snižavanje tlaka na predmetima koje treba sterilizirati pomoću crpke s tekućim prstenom (5) nakon mehaničke vakuumske crpke (4) kako bi se postigao potrebni tlak plazme;
Elimination of the residual vapour from the solution (ML) of hydrogen peroxide by way of dilution with filtered atmospheric air using the liquid ring pump (5); 
uklanjanje rezidualne pare iz otopine (ML) vodikovog peroksida razrjedivanjem s filtriranim atmosferskim zrakom pomoću crpke s tekućim prstenom (5);
Dilution of the vapour from the hydrogen peroxide by the injection of filtered air (11) into the chamber (1); 
razrjeđivanje pare iz vodikovog peroksida ubrizgavanjem filtriranog zraka (11) u komoru (1);
Generation of plasma from the residual atmospheric air with the excitation of pulsed DC in order to obtain an adequate temperature for sterilization; 
generiranje plazme iz rezidualnog atmosferskog zraka pobuđivanjem pulsom istosmjerne struje kako bi se postigla prikladna temperatura za sterilizaciju;
Generation of pulsed DC discharge plasma from atmospheric air in order to complement the sterilization and elimination of the residues; 
generiranje plazme pulsnim pražnjenjem istosmjerne struje iz atmosferskog zraka kako bi se dodatno pojačala sterilizacija i uklonili ostaci;
the articles (M), eventually packed with non-woven surgical grade material, are placed on the stands (12); 
predmeti (M), koji se po izboru mogu omotati netkanim materijalom kirurške kakvoće, postave se na stalke (12);
the vacuum is induced in the chamber (1) by means of the liquid ring pump (5) and the valve (6), reducing the pressure to approximately 100 mbar; 
u komori se inducira vakuum (1) pomoću crpke s tekućim prstenom (5) i ventila (6), čime se tlak snižava na otprilike 100 mbar;
the pressure is reduced by the mechanical high-vacuum pump (4), and energy is supplied simultaneously in order for plasma to be generated, which continues to be applied until the obtaining of the sterilization conditions, and the pressure reaches approximately 2x10-1 mbar; 
tlak se snižava pomoću mehaničke crpke za visoki vakuum (4), a istovremeno se dobavlja energija za generiranje plazme, koja se neprekidno isporučuje sve dok se ne postignu uvjeti za sterilizaciju, a tlak ne dostigne oko 2×10-1 mbar;
after the pumping to vacuum has been interrupted and the chamber isolated by the valve (7), the stabilized solution (ML) of hydrogen peroxide is vaporised in vacuum with heating; 
nakon što se prekine crpljenje do vakuuma i komora izolira ventilom (7), stabilizirana se otopina (ML) vodikovog peroksida ispari zagrijavanjem u vakuumu;
the filtered atmospheric air is admitted into the chamber via a HEPA® filter (11), raising the pressure to atmospheric pressure; and 
u komoru se pusti filtrirani atmosferski zrak preko HEPA® filtra (11), čime se tlak podiže na razinu atmosferskog tlaka; i
the pressure is again reduced by the liquid ring pump (5); items (h) and (i) are eventually repeated one or more times; 
tlak se ponovo snizi pomoću crpke s tekućim prstenom (5); stavke (h) i (i) se po izboru ponavljaju jednom ili više puta;
the pressure is reduced by the mechanical vacuum pump to a pressure in the range from 5x10-2 mbar to 5x10-1 mbar; 
tlak se snižava pomoću mehaničke vakuumske crpke do tlaka u rasponu od 5×10-2 mbar do 5×10-1 mbar;
pulsed DC discharge plasma is generated from atmospheric air in order to complement the sterilization process and eliminate the residues; and 
iz atmosferskog zraka generira se plazma pulsom istosmjerne struje kako bi se upotpunio postupak sterilizacije i uklonili ostaci; i
filtered air is admitted by the HEPA® filter in order for the chamber (1) to be opened. 
pušta se filtrirani zrak preko HEPA® filtra kako bi se komora (1) otvorila.